Collegium Pharmaceutical, Inc. COLL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $796.33M+2.0% | $780.57M+3.1% | $757.07M+7.1% | $707.01M+6.4% | $664.28M+5.2% | ||
| $313.15M-1.3% | $317.31M-2.0% | $323.9M+5.8% | $306.22M+8.9% | $281.07M+10.6% | ||
| $483.18M+4.3% | $463.26M+6.9% | $433.17M+8.1% | $400.79M+4.6% | $383.21M+1.6% | ||
| 60.7%+1.3pp | 59.3%+2.1pp | 57.2%+0.5pp | 56.7%-1.0pp | 57.7%-2.1pp | ||
| $294.73M+3.5% | $284.8M+1.6% | $280.25M+1.9% | $275.11M+12.4% | $244.8M+16.4% | ||
| $294.33M+3.8% | $283.62M+2.7% | $276.18M+1.9% | $271.05M+12.4% | $241.1M+16.2% | ||
| $294.33M+3.8% | $283.62M+2.7% | $276.18M+1.9% | $271.05M+12.4% | $241.1M+16.2% | ||
| $188.85M+5.1% | $179.64M+14.4% | $156.99M+21.0% | $129.74M-8.7% | $142.11M-16.4% | ||
| 23.7%+0.7pp | 23%+2.3pp | 20.7%+2.4pp | 18.4%-3.0pp | 21.4%-5.5pp | ||
| $77.38M-6.0% | $82.31M-3.9% | $85.67M+4.1% | $82.3M+6.3% | $77.43M+4.7% | ||
| $12.77M+13.1% | $11.29M+18.4% | $9.54M-1.7% | $9.7M-17.2% | $11.71M-16.2% | ||
| $108.24M+16.9% | $92.62M+14.6% | $80.85M+52.6% | $53M-18.6% | $65.07M-34.0% | ||
| $33.29M+11.9% | $29.75M+32.8% | $22.41M+34.0% | $16.73M-21.0% | $21.17M-27.9% | ||
| $74.95M+19.2% | $62.87M+7.6% | $58.44M+61.1% | $36.27M-17.4% | $43.89M-36.6% | ||
| 9.4%+1.4pp | 8.1%+0.3pp | 7.7%+2.6pp | 5.1%-1.5pp | 6.6%-4.3pp | ||
| $2.04+19.3% | $1.71+6.2% | $1.61+54.8% | $1.04-14.8% | $1.22-34.4% | ||
| $2.37+18.5% | $2.00+8.1% | $1.85+62.3% | $1.14-16.2% | $1.36-36.4% | ||
| 158.7M+4.8% | 151.4M0.0% | 151.5M-0.5% | 152.2M-0.9% | 153.5M-5.3% | ||
| 127.1M+0.2% | 126.8M-0.3% | 127.3M-0.5% | 127.9M-0.5% | 128.6M-0.4% | ||
| —— | —— | —— | —— | $179.45M+8.6% | ||
| -$396K+66.5% | -$1.18M+71.0% | -$4.08M-0.5% | -$4.06M-9.7% | -$3.7M-27.0% | ||
| $12.77M+13.1% | $11.29M+18.4% | $9.54M-1.7% | $9.7M-17.2% | $11.71M-16.2% | ||
| $796.33M+2.0% | $780.57M+3.1% | $757.07M+7.1% | $707.01M+6.4% | $664.28M+5.2% | ||
| $188.85M+5.1% | $179.64M+14.4% | $156.99M+21.0% | $129.74M-8.7% | $142.11M-16.4% | ||
| $247.87M+3.6% | $239.29M-12.1% | $272.23M-4.7% | $285.7M-14.0% | $332.4M-2.0% | ||
| $247.87M+3.6% | $239.29M-12.1% | $272.23M-4.7% | $285.7M-14.0% | $332.4M-2.0% | ||
| 31.1%+0.5pp | 30.7%-5.3pp | 36%-4.5pp | 40.4%-9.6pp | 50%-3.7pp | ||
| $188.85M+5.1% | $179.64M+14.4% | $156.99M+21.0% | $129.74M-8.7% | $142.11M-16.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s revenue?
- Collegium Pharmaceutical, Inc. (COLL) generated $796.3M in revenue over the trailing twelve months, up 19.9% year over year.
- Is Collegium Pharmaceutical, Inc. profitable?
- Collegium Pharmaceutical, Inc. reported $74.9M in net income over the trailing twelve months, a 9.4% net margin.
- What are Collegium Pharmaceutical, Inc.'s profit margins?
- Gross margin is 60.7% and operating margin is 23.7%, with a 9.4% net margin.
- What is Collegium Pharmaceutical, Inc.'s earnings per share?
- Collegium Pharmaceutical, Inc.'s diluted EPS over the trailing twelve months is $2.04.
- Where does Collegium Pharmaceutical, Inc.'s income statement data come from?
- Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
